Search

Editors

Richard L. Cassin Publisher and Editor

Andy Spalding Senior Editor

Jessica Tillipman Senior Editor

Elizabeth K. Spahn Editor Emeritus

Cody Worthington Contributing Editor

Julie DiMauro Contributing Editor

Thomas Fox Contributing Editor

Marc Alain Bohn Contributing Editor

Bill Waite Contributing Editor

Shruti J. Shah Contributing Editor

Russell A. Stamets Contributing Editor

Richard Bistrong Contributing Editor 

Eric Carlson Contributing Editor

Bill Steinman Contributing Editor

Aarti Maharaj Contributing Editor


FCPA Blog Daily News

« Voices Against Corruption | Main | The Music Didn’t Die After All »
Tuesday
Aug072012

SEC Subpoena For Teva

Israel's Teva Pharmaceutical Industries Limited said it was subpoenaed by the SEC because of potential FCPA compliance problems in Latin America.

Drug-maker Teva, one of Israel's biggest companies, said in an SEC filing last week it is cooperating with the U.S. government and conducting its own internal investigation.

Teva didn't provide other details or say what triggered the SEC subpoena that came in July.

The SEC doesn't comment on pending FCPA investigations or disclose unresolved whistleblower complaints.

*     *     *

Here's Teva's full FCPA disclosure from its August 2, 2012 Form 6-K (Report of Foreign Private Issuer):

Teva received a subpoena dated July 9, 2012 from the SEC to produce documents with respect to compliance with the Foreign Corrupt Practice Act ("FCPA") in Latin America. Teva is cooperating with the government. Teva is also conducting a voluntary investigation into certain business practices which may have FCPA implications and has engaged independent counsel to assist in its investigation. These matters are in their early stages and no conclusion can be drawn at this time as to any likely outcomes.

________________

Research courtesy of ethiXbase, the world's largest database of anti-corruption legislation, gift-giving regulations, investigations, and enforcement actions.

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Post:
 
All HTML will be escaped. Hyperlinks will be created for URLs automatically.